List of Excipients in Branded Drug ADVIL SINUS CONGESTION AND PAIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	ADVIL SINUS CONGESTION AND PAIN	ibuprofen, phenylephrine hydrochloride	0573-0199	ACESULFAME POTASSIUM
Haleon US Holdings LLC	ADVIL SINUS CONGESTION AND PAIN	ibuprofen, phenylephrine hydrochloride	0573-0199	CARNAUBA WAX
Haleon US Holdings LLC	ADVIL SINUS CONGESTION AND PAIN	ibuprofen, phenylephrine hydrochloride	0573-0199	CELLULOSE, MICROCRYSTALLINE
Haleon US Holdings LLC	ADVIL SINUS CONGESTION AND PAIN	ibuprofen, phenylephrine hydrochloride	0573-0199	CROSCARMELLOSE SODIUM

Advil Sinus Congestion and Pain Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

Advil Sinus Congestion and Pain is an over-the-counter combination product containing ibuprofen 200 mg and phenylephrine hydrochloride 10 mg per caplet. Its commercial position depends on reliable immediate-release performance, tablet swallowability, packaging stability, and regulatory flexibility as FDA reassesses oral phenylephrine effectiveness. The strongest excipient opportunities are low-cost formulation upgrades, preservative-free manufacturing controls, alternate dosage forms, and reformulation strategies that retain the Advil brand while reducing dependence on oral phenylephrine.

What active ingredients and dosage forms does Advil Sinus Congestion and Pain contain?

The standard U.S. product combines a nonsteroidal anti-inflammatory drug with an oral nasal decongestant.

Product attribute	Current commercial profile
Brand	Advil Sinus Congestion and Pain
Active ingredients	Ibuprofen 200 mg; phenylephrine hydrochloride 10 mg
Dosage form	Immediate-release oral caplet or tablet
Regulatory category	OTC drug
Therapeutic claims	Temporary relief of sinus pressure, nasal congestion, headache, fever, and minor aches and pains associated with the common cold or sinusitis
Primary brand owner in the U.S.	Haleon
Drug category	NSAID plus sympathomimetic decongestant
U.S. prescription status	Nonprescription

Ibuprofen provides analgesic, antipyretic, and anti-inflammatory activity. Phenylephrine hydrochloride is included for temporary nasal decongestant relief. FDA has proposed removing oral phenylephrine from the OTC nasal-decongestant monograph after concluding that available data do not support its effectiveness at the currently marketed oral dose. The proposal concerns efficacy, not a finding that oral phenylephrine is unsafe when used as labeled.[1]

What excipients are used in Advil Sinus Congestion and Pain?

Public product labeling identifies inactive ingredients for the marketed caplet formulation. Exact excipient composition can vary by manufacturing site, market, package configuration, or product revision.

Commonly identified excipient classes include:

Excipient or excipient class	Likely functional role
Microcrystalline cellulose	Diluent and tablet-supporting filler
Pregelatinized starch	Binder, filler, and disintegrant
Croscarmellose sodium	Superdisintegrant for rapid tablet breakup
Crospovidone	Superdisintegrant supporting immediate release
Povidone	Binder and granulation aid
Colloidal silicon dioxide	Glidant and moisture-control aid
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Polyethylene glycol	Plasticizer for film coating
Titanium dioxide	Opacifier and colorant
Sodium lauryl sulfate	Wetting agent or processing aid

The formulation objective is rapid disintegration without compromising mechanical strength. Because the product combines two active ingredients with different powder-flow and compression properties, excipient selection must support content uniformity for both ibuprofen and the lower-dose phenylephrine component.

Immediate-release performance

The principal technical requirement is prompt release of both active ingredients. A high level of hydrophobic lubricant, excessive compression force, or an overbuilt film coat can delay dissolution. Croscarmellose sodium and crospovidone provide complementary disintegration mechanisms, but their effectiveness depends on particle size, granulation process, compression force, and tablet porosity.

Ibuprofen is poorly water-soluble relative to many common OTC actives. Formulators therefore have to balance wetting, particle dispersion, and tablet breakup. Sodium lauryl sulfate can improve wetting, but its use is constrained by taste, gastrointestinal tolerability, and consumer sensitivity concerns.

Manufacturing robustness

The commercial formulation must tolerate high-volume production, coating, bottling, and extended shelf storage. Colloidal silicon dioxide improves flow, while magnesium stearate reduces tooling friction. Excessive lubricant blending can reduce tablet hardness and slow dissolution. These tradeoffs create opportunities for process-controlled excipient optimization without changing the active ingredients.

What regulatory risks affect the excipient strategy for Advil Sinus Congestion and Pain?

The largest regulatory risk is the FDA’s proposed determination that oral phenylephrine is not effective as an OTC nasal decongestant at the marketed dose.[1] If FDA finalizes the action, products relying on phenylephrine would face reformulation, relabeling, discontinuation, or a transition to another regulatory basis.

Oral phenylephrine reformulation

A replacement product could use:

1. Ibuprofen alone, with sinus-pain positioning but no oral decongestant claim.
2. Ibuprofen combined with a different legally marketable decongestant, subject to monograph and safety constraints.
3. A nasal delivery component, although that would create a different dosage form, device, manufacturing process, and labeling strategy.
4. A non-drug consumer-health product positioned around saline, humidification, or mechanical nasal relief.

Each path changes the excipient profile. Removing phenylephrine reduces blend-uniformity complexity and may allow a smaller tablet. Replacing it with another active may require new compatibility, dissolution, stability, and labeling work.

Label and excipient disclosure

The product must list inactive ingredients in accordance with FDA labeling rules. Changes to colorants, coating systems, flavoring agents, or allergen-related components can affect label review, consumer perception, and retailer acceptance even when the active ingredients remain unchanged.

What formulation patents protect Advil Sinus Congestion and Pain?

The commercially relevant protection is primarily brand, trade dress, regulatory exclusivity, manufacturing know-how, and distribution scale rather than a currently visible drug-patent estate.

Because Advil Sinus Congestion and Pain is an OTC product based on long-established active ingredients, it is not expected to rely on a conventional new-molecule patent portfolio. The combination of ibuprofen and phenylephrine is also technically mature. Any legacy formulation patents would need to be assessed against expiration, claim scope, prosecution history, and whether the marketed product practices the claims.

Protection category	Strategic relevance
Active-ingredient patents	Limited; ibuprofen and phenylephrine are long-established compounds
Combination patents	Potentially relevant only if claims cover a specific ratio, dosage form, or release profile
Formulation patents	Possible protection for coating, taste masking, stability, or dissolution control
Method-of-use patents	Limited value for broad OTC sinus and pain claims
Trademark rights	High commercial relevance for Advil branding
Trade dress	Relevant to shelf recognition and retailer placement
Manufacturing know-how	Important for blend uniformity, coating, compression, and quality control
Regulatory pathway	OTC monograph compliance is more important than Orange Book exclusivity

No Orange Book listing or FDA Paragraph IV framework ordinarily applies to a conventional OTC monograph product. An OTC manufacturer does not obtain the same five-year new chemical entity exclusivity or three-year clinical-investigation exclusivity associated with an approved prescription product under an NDA.

When does Advil Sinus Congestion and Pain lose exclusivity?

There is no single patent expiration date that controls market entry for the standard OTC product. The active ingredients are long off-patent, and the principal commercial barriers are brand equity, retailer access, manufacturing capability, and regulatory compliance.

A private-label manufacturer can generally market an equivalent OTC combination if it meets the applicable FDA monograph requirements, labeling rules, current good manufacturing practice standards, and applicable trademark restrictions. It cannot use Advil branding or confusingly similar trade dress.

The practical exclusivity timeline is therefore:

Period	Commercial condition
Historical period	Brand established through Advil analgesic franchise
Current period	OTC competition permitted from store brands and national brands
FDA phenylephrine review period	Product composition and claims exposed to regulatory change
Post-final FDA action	Possible reformulation, relabeling, or product withdrawal
Long term	Brand and distribution remain the primary barriers

How strong is the patent estate for Advil Sinus Congestion and Pain?

The patent estate is likely weak as a barrier to generic or private-label competition. The commercial moat is stronger than the patent moat.

Strengths

• High consumer recognition for Advil.
• Established retail distribution.
• Familiar ibuprofen dosage strength.
• Simple immediate-release manufacturing platform.
• Low technical barrier to producing an equivalent caplet.
• Ability to extend the franchise through adjacent sinus, cold, and flu products.

Weaknesses

• Long-established active ingredients.
• No meaningful new-molecule exclusivity.
• No conventional Orange Book blocking strategy.
• Private-label products can compete on price.
• Oral phenylephrine regulatory risk affects the combination rationale.
• Formulation claims, if any, are likely narrow and vulnerable to design-around strategies.

A competitor could use different binders, disintegrants, lubricants, coating polymers, or colorants while preserving the same active ingredients and labeled strengths. That reduces the practical value of narrow formulation patents.

What commercial opportunities exist for excipient suppliers and manufacturers?

The main opportunities are formulation modernization and regulatory-driven product redesign.

1. Phenylephrine-free sinus pain products

If oral phenylephrine loses its monograph status, an ibuprofen-only product could retain the Advil brand while narrowing claims to pain and fever relief. This would reduce active-load complexity and could support:

• Smaller tablets.
• Faster development timelines.
• Simpler blend uniformity controls.
• Lower raw-material cost.
• Fewer active-excipient compatibility questions.

Excipient suppliers could position low-moisture, direct-compression systems for ibuprofen tablets, especially combinations of microcrystalline cellulose, starch-based disintegrants, and high-functionality binders.

2. Fast-disintegrating caplets

A faster-disintegrating formulation could improve consumer perception without making a therapeutic equivalence claim beyond the applicable regulatory framework. Opportunities include:

• Co-processed excipients.
• Low-viscosity film coats.
• Improved wetting systems.
• Optimized crospovidone or croscarmellose grades.
• Lower lubricant concentrations.
• Tablet structures engineered for rapid liquid penetration.

The product must avoid compromising hardness, friability, coating adhesion, or shelf life.

3. Smaller-dose or easier-to-swallow formats

Sinus products are often used by consumers experiencing headache, congestion, or sore throat. Smaller caplets, softgels, liquid-filled capsules, and orally disintegrating technologies could address swallowability. Softgel development would require a different compatibility and encapsulation platform, particularly because ibuprofen solubility and phenylephrine stability differ from conventional compressed-tablet behavior.

4. Dye-free and simplified excipient systems

Dye-free, titanium-dioxide-free, or reduced-excipient formulations may support retailer requirements and consumer-label preferences. A simplified excipient system can also reduce supply-chain exposure. The tradeoff is that color and coating changes can affect brand recognition and tablet identification.

5. Sustainable packaging and excipient sourcing

The strongest sustainability opportunities may be outside the tablet itself. They include:

• Reduced-plastic bottles.
• Higher recycled-content packaging.
• Blister systems with lower material intensity.
• Regional excipient sourcing.
• Lower-temperature coating processes.
• Reduced solvent use in film coating.

These changes may create meaningful commercial value without altering the active formulation.

Which companies are challenging Advil Sinus Congestion and Pain?

Competition comes from three groups:

Competitor group	Examples	Competitive basis
Store brands	Retailer-branded ibuprofen and sinus products	Lower price and equivalent OTC positioning
National OTC brands	Tylenol Sinus, Mucinex Sinus-Max, Sudafed combinations	Brand recognition and broader cold-and-flu portfolios
Generic manufacturers	Private-label and contract manufacturers	Low-cost monograph-compliant products

The principal competitive risk is not a patent challenger. It is substitution by lower-priced private-label products or by other branded products using different decongestant strategies.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate. A capable OTC manufacturer can produce the product, but quality requirements remain material.

Key controls include:

• Uniform distribution of 10 mg phenylephrine hydrochloride in the blend.
• Consistent ibuprofen assay and dissolution.
• Control of tablet hardness and friability.
• Lubrication-time management.
• Coating weight and adhesion.
• Moisture protection.
• Stability under temperature and humidity stress.
• Accurate OTC Drug Facts labeling.

The most defensible know-how lies in scale-up, process validation, raw-material specifications, and supply reliability. These barriers are operational rather than exclusionary. They can delay a competitor but generally do not prevent entry.

What generic launch risks exist for Advil Sinus Congestion and Pain?

Generic and private-label entry risk is high because the active ingredients are mature and the product does not depend on a novel active substance. Launch risk is concentrated in three areas:

1. FDA action on oral phenylephrine.
2. Retailer preference for private-label products.
3. Consumer movement toward single-ingredient pain products or alternative decongestant formats.

A phenylephrine regulatory change could create a short-term supply disruption and a broader reformulation cycle. Companies with flexible tablet platforms, established ibuprofen supply, and rapid label-change capabilities would be positioned to capture share.

What is the revenue exposure for the Advil brand?

Haleon reports Advil within broader consumer-health brand and regional financial disclosures rather than providing a consistently separate public revenue line for each SKU. Product-level revenue for Advil Sinus Congestion and Pain is therefore not independently reported in standard public filings.

Exposure is best assessed through:

• Advil brand sales.
• Sinus and cold category performance.
• U.S. retail scanner data.
• Product availability and shelf placement.
• Mix between combination and single-ingredient products.
• The commercial outcome of FDA’s phenylephrine review.

The specific SKU’s revenue risk is higher than its patent risk because a reformulation or claim change could reduce consumer recognition and retailer continuity even without a legal market-entry event.

Key Takeaways

• Advil Sinus Congestion and Pain is an OTC ibuprofen 200 mg and phenylephrine hydrochloride 10 mg combination product.
• Its formulation depends on immediate-release disintegration, blend uniformity, coating control, and moisture stability.
• Patent protection is not the primary commercial barrier; brand, distribution, manufacturing know-how, and regulatory compliance are more important.
• FDA’s oral phenylephrine review is the central strategic risk.
• A phenylephrine-free ibuprofen product is the most direct reformulation path.
• Excipient suppliers can compete through co-processed excipients, rapid-disintegration systems, dye-free formulations, and lower-cost direct compression platforms.
• Generic and private-label competition is structurally high.
• Product-level revenue exposure is not separately disclosed by Haleon.

FAQs About Advil Sinus Congestion and Pain Excipient Strategy

Does Advil Sinus Congestion and Pain have Orange Book exclusivity?

No conventional Orange Book exclusivity is expected for this OTC monograph-based product. Its market position is driven primarily by brand and distribution rather than NDA-based exclusivity.

Could Advil Sinus Congestion and Pain be reformulated without phenylephrine?

Yes. An ibuprofen-only version could retain pain and fever claims but would not provide an oral decongestant ingredient. The resulting product would require revised labeling and commercial positioning.

Are the inactive ingredients in every Advil sinus product identical?

No. Inactive ingredients can vary by dosage form, market, manufacturing site, and product revision. The package label for the specific SKU controls.

Can a generic manufacturer copy the Advil caplet formulation?

A manufacturer can market an equivalent OTC product if it complies with FDA requirements and avoids Advil trademarks and confusingly similar trade dress. It can use different excipients and still match the active ingredients and labeled strengths.

What is the most valuable excipient innovation for this product?

A robust immediate-release platform that improves disintegration and dissolution while preserving tablet strength, stability, and low manufacturing cost is the most commercially relevant innovation. A flexible platform that can operate with or without phenylephrine has added strategic value.

References

1. U.S. Food and Drug Administration. (2024). Phenylephrine hydrochloride oral solution, extended release, and tablet dosage forms: Proposed order and regulatory review materials. FDA.
2. U.S. Food and Drug Administration. (2023). Drug Facts label requirements for over-the-counter human drug products. FDA.
3. U.S. Food and Drug Administration. (2023). Inactive ingredient database. FDA.
4. Haleon plc. (2024). Annual report 2023. Haleon.
5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.